Ferrante

Taysha Gene Therapies is a clinical-stage biotechnology company focused on developing AAV-based gene therapies for severe monogenic diseases of the central nervous system. Originally founded as Ferrante Biotech in 2019, the company rebranded to Taysha in early 2020 following a significant seed investment. Its lead clinical program, TSHA-102, is an AAV9 gene therapy currently being evaluated for the treatment of Rett syndrome. The company utilizes a proprietary platform to design and optimize gene replacement therapies, incorporating regulatory elements like the miRARE technology to control transgene expression. Taysha is headquartered in Dallas, Texas, and maintains a strategic focus on rare neurological disorders with high unmet medical needs.